TY - JOUR
T1 - Longitudinal Metabolic Profiling of Maternal Obesity, Gestational Diabetes, and Hypertensive Pregnancy Disorders
AU - Kivelä, Jemina
AU - Sormunen-Harju, Heidi
AU - Girchenko, Polina V.
AU - Huvinen, Emilia
AU - Stach-Lempinen, Beata
AU - Kajantie, Eero
AU - Villa, Pia M.
AU - Reynolds, Rebecca M.
AU - Hämäläinen, Esa K.
AU - Lahti-Pulkkinen, Marius
AU - Murtoniemi, Katja K.
AU - Laivuori, Hannele
AU - Eriksson, Johan G.
AU - Räikkönen, Katri
AU - Koivusalo, Saila B.
N1 - Funding Information:
The PREDO project has been supported by EVO research funding (a special Finnish state subsidy for health science research), Academy of Finland, Signe and Ane Gyllenberg Foundation, Sigrid Juselius Foundation, University of Helsinki Research Funds, Finnish Medical Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Jane and Aatos Erkko Foundation, and P?ivikki and Sakari Sohlberg Foundation. The RADIEL project has been supported by the Alfred Kordelin Foundation, Juho Vainio Foundation, Ahokas Foundation, the Finnish Foundation for Cardiovascular Disease, special state subsidy for health science research of Helsinki University Hospital (HUH), Samfundet Folkhalsan, Finska Lakaresallskapet, Viipuri Tuberculosis Foundation, The Finnish Diabetes Research Foundation. R.R. acknowledges the support of the British Heart Foundation (RE/18/5/34216).
Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society.
PY - 2021
Y1 - 2021
N2 - Context: Comprehensive assessment of metabolism in maternal obesity and pregnancy disorders can provide information about the shared maternal-fetal milieu and give insight into both maternal long-term health and intergenerational transmission of disease burden. Objective: To assess levels, profiles, and change in the levels of metabolic measures during pregnancies complicated by obesity, gestational diabetes (GDM), or hypertensive disorders. Design, Setting and Participants: A secondary analysis of 2 study cohorts, PREDO and RADIEL, including 741 pregnant women. Main Outcome Measures: We assessed 225 metabolic measures by nuclear magnetic resonance in blood samples collected at median 13 [interquartile range (IQR) 12.4-13.7], 20 (IQR 19.3-23.0), and 28 (27.0-35.0) weeks of gestation. Results: Across all 3 time points women with obesity [body mass index (BMI) ≥ 30kg/m2] in comparison to normal weight (BMI 18.5-24.99 kg/m2) had significantly higher levels of most very-low-density lipoprotein-related measures, many fatty and most amino acids, and more adverse metabolic profiles. The change in the levels of most metabolic measures during pregnancy was smaller in obese than in normal weight women. GDM, preeclampsia, and chronic hypertension were associated with metabolic alterations similar to obesity. The associations of obesity held after adjustment for GDM and hypertensive disorders, but many of the associations with GDM and hypertensive disorders were rendered nonsignificant after adjustment for BMI and the other pregnancy disorders. Conclusions: This study shows that the pregnancy-related metabolic change is smaller in women with obesity, who display metabolic perturbations already in early pregnancy. Metabolic alterations of obesity and pregnancy disorders resembled each other suggesting a shared metabolic origin.
AB - Context: Comprehensive assessment of metabolism in maternal obesity and pregnancy disorders can provide information about the shared maternal-fetal milieu and give insight into both maternal long-term health and intergenerational transmission of disease burden. Objective: To assess levels, profiles, and change in the levels of metabolic measures during pregnancies complicated by obesity, gestational diabetes (GDM), or hypertensive disorders. Design, Setting and Participants: A secondary analysis of 2 study cohorts, PREDO and RADIEL, including 741 pregnant women. Main Outcome Measures: We assessed 225 metabolic measures by nuclear magnetic resonance in blood samples collected at median 13 [interquartile range (IQR) 12.4-13.7], 20 (IQR 19.3-23.0), and 28 (27.0-35.0) weeks of gestation. Results: Across all 3 time points women with obesity [body mass index (BMI) ≥ 30kg/m2] in comparison to normal weight (BMI 18.5-24.99 kg/m2) had significantly higher levels of most very-low-density lipoprotein-related measures, many fatty and most amino acids, and more adverse metabolic profiles. The change in the levels of most metabolic measures during pregnancy was smaller in obese than in normal weight women. GDM, preeclampsia, and chronic hypertension were associated with metabolic alterations similar to obesity. The associations of obesity held after adjustment for GDM and hypertensive disorders, but many of the associations with GDM and hypertensive disorders were rendered nonsignificant after adjustment for BMI and the other pregnancy disorders. Conclusions: This study shows that the pregnancy-related metabolic change is smaller in women with obesity, who display metabolic perturbations already in early pregnancy. Metabolic alterations of obesity and pregnancy disorders resembled each other suggesting a shared metabolic origin.
KW - biomolecular
KW - diabetes
KW - gestational
KW - hypertension
KW - metabolomics
KW - nuclear magnetic resonance
KW - pre-eclampsia
KW - pregnancy
KW - pregnant women
U2 - 10.1210/clinem/dgab475
DO - 10.1210/clinem/dgab475
M3 - Article
C2 - 34185058
AN - SCOPUS:85119512153
VL - 106
SP - E4372-E4388
IS - 11
ER -